Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition
about
Low-dose rate brachytherapy for men with localized prostate cancerAssociation of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomyProgress of molecular targeted therapies for prostate cancersA critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentPre- and post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancerPredictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapyChemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRadical Prostatectomy versus External Beam Radiotherapy for cT1-4N0M0 Prostate Cancer: Comparison of Patient Outcomes Including MortalityExpression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samplesHypermethylation of genes for diagnosis and risk stratification of prostate cancerCystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibodyPostoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.CYP17 polymorphisms and prostate cancer outcomes.Positive surgical margins at radical prostatectomy predict prostate cancer specific mortalityPredictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience.Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.Outcome of postoperative radiotherapy following radical prostatectomy: a single institutional experience.Genetic markers associated with early cancer-specific mortality following prostatectomyClinical management and burden of prostate cancer: a Markov Monte Carlo model.Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.MALDI-target integrated platform for affinity-captured protein digestionHigh progesterone receptor expression in prostate cancer is associated with clinical failure.Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteinsVariations among experienced surgeons in cancer control after open radical prostatectomy.NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer.Role of Surgery in locally advanced prostate cancerManagement of biochemical recurrence after primary localized therapy for prostate cancerReview of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.Salvage radiotherapy after radical prostatectomy: outcomes and prognostic factors especially focusing on pathological findings.An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortalityThe incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience.Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesIL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.
P2860
Q24235544-E6DC15BD-D337-4E2F-B8CF-1274CE2ADC65Q24652928-B2D0C960-B8EB-4C10-9211-CB5DB168C3C1Q26823014-95066BB8-A7BE-4260-AC4E-A2BAA895BDF8Q26862558-4577F2D9-391B-4E3B-AF0A-8B89C273C8CEQ28539777-3DF7CB8C-4AC3-4B2E-8798-6EEF98512E02Q28541955-E1DABC0E-54B2-48A4-A3FD-11633FBEA3C8Q28542841-494F2969-EEC4-4E58-95DF-11CD9C4FE6ABQ28550520-791C5724-31D3-4A64-BB5A-6B8F7E9BC950Q30499412-9E29CAC0-35B5-4CBD-9B1C-865773FF8C83Q30859743-9199D0D7-72A8-4350-8335-822D6AFD05FBQ33410858-91D18CC2-01ED-4ABB-BD06-C99F5EFE59AEQ33517129-1ECEEAE0-F1EF-45FB-A747-68803AECADABQ33684005-E1CEFDF0-D8EF-4E0B-B7B2-E9CFFD69C52DQ33705993-BDB8EBEE-724A-4B46-B153-9CE8564A6AD2Q33766462-26DAC194-CDFF-4A4D-AA77-058F03056AF2Q33884273-F266861D-A8CF-4A17-8865-D6F232FA2897Q33990394-32B9306C-9EAA-47E9-87B7-D42613349648Q33993472-CEC1A6F1-5319-401E-AF06-899FE83537D0Q34008499-55E5ABB9-5491-4948-92D0-2DA910341158Q34232239-714DD410-E0CA-411D-A8A0-19CCA089895FQ34267902-7451C252-F27F-443F-87B8-7363F7DE0A5CQ34325452-0ED00DAD-4EB2-480F-A418-9C1FC4B39A8EQ34340799-5AF5A685-D728-4CDC-B1CA-C74C14DB1FCEQ34634410-2E0F4A5D-43A3-4494-928D-4A90B0E0DB03Q34872970-0B74C431-DA43-428D-8312-A9C6B1BF66AEQ35072160-50EBBBE5-9AC1-46F9-9A3A-70C7A342B342Q35130208-6D64AD7E-92C9-4CAC-B0E3-11D955ADD64BQ35188264-7F309E01-8EBD-4A87-BE35-E0983BBD99EEQ35264079-0B708F20-7B6E-49CB-A881-DA3CEF1327B5Q35630139-ED2F07C0-F9F3-4AEB-9A08-62159F7B9636Q35676114-FD740966-6ADB-4727-956B-DE1CA499FBDCQ35739865-4907EE0D-712C-41C3-A737-352F48D68EC4Q35796878-FA0DA280-1279-41BD-8CBD-4AB1799E8E45Q35981941-C9142828-624B-48C2-80F8-232D9A6493C6Q36010923-F8F18383-4656-4D00-95B2-CA2F5551875BQ36197823-80F9FFDB-22BE-4A6E-AFBF-F688F233F505Q36286694-F6DFCE60-9234-4467-9847-D44683FB1E3EQ36290824-8651483F-B874-4CE6-9390-F03771CF5D36Q36326373-D96C17E8-EBCF-481A-9AF9-0045312357D9Q36335722-AF84960A-9481-412A-8199-53AB7E30F6AC
P2860
Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition
description
im August 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2006
@uk
name
Defining Biochemical Recurrenc ...... for a Standardized Definition
@en
Defining Biochemical Recurrenc ...... for a Standardized Definition
@nl
type
label
Defining Biochemical Recurrenc ...... for a Standardized Definition
@en
Defining Biochemical Recurrenc ...... for a Standardized Definition
@nl
prefLabel
Defining Biochemical Recurrenc ...... for a Standardized Definition
@en
Defining Biochemical Recurrenc ...... for a Standardized Definition
@nl
P2093
P356
P1476
Defining Biochemical Recurrenc ...... for a Standardized Definition
@en
P2093
Andrew J. Stephenson
Fernando J. Bianco
James A. Eastham
Michael W. Kattan
Peter T. Scardino
Zohar A. Dotan
P304
P356
10.1200/JCO.2005.04.0756
P407
P50
P577
2006-08-20T00:00:00Z